It plays a powerful role in protecting sperm from oxidative stress, which can otherwise damage DNA and lower fertilisation potential
Many patients also consider changing GLP 1 medication because of a weight loss plateau
Idris I, Abdulla H, Tilbrook S, et al
Summary: Retatrutide is not currently available in the UK or globally, as it remains an investigational medicine without marketing authorisation, accessible only through authorised clinical trials as of mid-2025
Tirzepatide is a dual GIP/GLP-1 receptor agonist that produces mean body weight reductions of 20.9% at 72 weeks by delaying gastric emptying, suppressing ghrelin rebound, and enhancing glucose-dependent insulin secretion
Business Model Noom is a subscription-based digital health platform that offers personalized weight loss and wellness programs